January 3, 1996

Carcinogenicity of Lipid-Lowering Drugs

Author Affiliations

From the Departments of Laboratory Medicine (Dr Newman), Pediatrics (Dr Newman), and Epidemiology and Biostatistics (Drs Newman and Hulley), and the Robert Wood Johnson Clinical Scholars Program (Dr Newman), School of Medicine, University of California, San Francisco.

JAMA. 1996;275(1):55-60. doi:10.1001/jama.1996.03530250059028

Objective.  —To review the findings and implications of studies of rodent carcinogenicity of lipid-lowering drugs.

Data Sources.  —Summaries of carcinogenicity studies published in the 1992 and 1994 Physicians' Desk Reference (PDR), additional information obtained from the US Food and Drug Administration, and published articles identified by computer searching, bibliographies, and consultation with experts.

Study Sample.  —We tabulated rodent carcinogenicity data from the 1994 PDR for all drugs listed as "hypolipidemics." For comparison, we selected a stratified random sample of antihypertensive drugs. We also reviewed methods and interpretation of carcinogenicity studies in rodents and results of clinical trials in humans.

Data Synthesis.  —All members of the two most popular classes of lipid-lowering drugs (the fibrates and the statins) cause cancer in rodents, in some cases at levels of animal exposure close to those prescribed to humans. In contrast, few of the antihypertensive drugs have been found to be carcinogenic in rodents. Evidence of carcinogenicity of lipid-lowering drugs from clinical trials in humans is inconclusive because of inconsistent results and insufficient duration of follow-up.

Conclusions.  —Extrapolation of this evidence of carcinogenesis from rodents to humans is an uncertain process. Longer-term clinical trials and careful postmarketing surveillance during the next several decades are needed to determine whether cholesterol-lowering drugs cause cancer in humans. In the meantime, the results of experiments in animals and humans suggest that lipid-lowering drug treatment, especially with the fibrates and statins, should be avoided except in patients at high short-term risk of coronary heart disease.(JAMA. 1996;275:55-60)